stoxline Quote Chart Rank Option Currency Glossary
Acorda Therapeutics, Inc. (ACOR)
0.661  -0.209 (-24.02%)    04-11 16:00
Open: 0.7838
High: 0.85
Volume: 321,668
Pre. Close: 0.87
Low: 0.6116
Market Cap: 1(M)
Technical analysis
2024-06-12 4:20:08 PM
Short term     
Mid term     
Targets 6-month :  0.8 1-year :  1.12
Resists First :  0.69 Second :  0.96
Pivot price 0.52
Supports First :  0.25 Second :  0.2
MAs MA(5) :  0.3 MA(20) :  0.5
MA(100) :  7.8 MA(250) :  11.05
MACD MACD :  -0.5 Signal :  -0.6
%K %D K(14,3) :  6.5 D(3) :  5.1
RSI RSI(14): 29.5
52-week High :  18.2 Low :  0.25
Price, MAs and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and BEARISH in mid-long term.
[ ACOR ] has closed above bottom band by 20.5%. Bollinger Bands are 82.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 33 bars. This is a sign that the market may be about to initiate a new trend.

Stock Price Prediction
If tomorrow: Open lower Open higher
High: 0.3 - 0.3 0.3 - 0.3
Low: 0.3 - 0.3 0.3 - 0.3
Close: 0.3 - 0.3 0.3 - 0.3
Company Description

Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. Acorda Therapeutics, Inc. was incorporated in 1995 and is headquartered in Ardsley, New York.

Headline News

Sun, 26 May 2024
Are Options Traders Betting on a Big Move in Acorda (ACOR) Stock? - Yahoo Canada Shine On

Wed, 03 Apr 2024
Acorda Therapeutics to be delisted from Nasdaq amid Chapter 11 By -

Wed, 03 Apr 2024
Acorda Therapeutics Announces Nasdaq Delisting Notification - Business Wire

Tue, 02 Apr 2024
Acorda Therapeutics' Strategic Bankruptcy and Asset Sale Plan - - TipRanks

Tue, 02 Apr 2024
Why Acorda Therapeutics Stock Is Down Nearly 90% - Benzinga

Tue, 02 Apr 2024
Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today? - InvestorPlace

Financial Analysis
Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Stock Basics & Statistics
Drug Manufacturers - Specialty & Generic
Shares Out 1 (M)
Shares Float 1 (M)
Held by Insiders 0.6 (%)
Held by Institutions 13.2 (%)
Shares Short 8 (K)
Shares Short P.Month 11 (K)
Stock Financials
EPS -203.58
EPS Est Next Qtrly 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) -127.17
Profit Margin -215 %
Operating Margin 3.9 %
Return on Assets (ttm) -5.8 %
Return on Equity (ttm) 0 %
Qtrly Rev. Growth 20.7 %
Gross Profit (p.s.) 0
Sales Per Share 94.86
EBITDA (p.s.) 6.77
Qtrly Earnings Growth 0 %
Operating Cash Flow -14 (M)
Levered Free Cash Flow 20 (M)
Stock Valuations
PE Ratio -0.01
PEG Ratio 0
Price to Book value -0.01
Price to Sales 0
Price to Cash Flow -0.03
Stock Dividends
Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.

StockChart iOS

StoxlineLite iOS

StoxlineLite iOS

OptionCalc iOS

StockChart Android

StoxlineLite Android

StoxlinePro Android

OptionCalc Android